TradingKey

关于 United Therapeutics Corp 公司

United Therapeutics Corporation 是一家制药公司。该公司营销和销售用于治疗肺动脉高压 (PAH) 的商业疗法：Tyvaso DPI（曲前列尼尔）吸入粉剂（Tyvaso DPI）；Tyvaso（曲前列尼尔）吸入溶液（雾化 Tyvaso），包括 Tyvaso 吸入系统；Remodulin（曲前列尼尔）注射液（Remodulin）；Orenitram（曲前列尼尔）缓释片（Orenitram）；和 Adcirca（他达拉非）片剂（Adcirca）。Tyvaso DPI 和雾化 Tyvaso 还获准用于治疗与间质性肺病 (PH-ILD) 相关的肺动脉高压。该公司还营销和销售用于治疗高风险神经母细胞瘤的肿瘤产品 Unituxin（dinutuximab）注射液（Unituxin）和用于 Remodulin 的 Remunity 泵（Remunity）。 Tyvaso DPI 是一种药械组合产品，融合了 MannKind 的 Afrezza（人胰岛素）吸入粉中使用的干粉配方技术和 Dreamboat 吸入装置技术。

公司简介

公司代码UTHR

公司名称United Therapeutics Corp

上市日期Jun 17, 1999

CEODr. Martine A. Rothblatt

员工数量1305

证券类型Ordinary Share

年结日Jun 17

公司地址1000 Spring St

城市SILVER SPRING

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编20910

电话13016089292

网址https://www.unither.com/

公司代码UTHR

上市日期Jun 17, 1999

CEODr. Martine A. Rothblatt

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

-0.06%

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

20.57K

+6.14%

Prof. Nilda Mesa, J.D.

Independent Director

5.47K

+12.08%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

Mr. Christopher Patusky, J.D.

Lead Independent Vice Chairman of the Board

2.59K

+29.50%

Ms. Jan Malcolm

Director

1.22K

+93.65%

Gov. Thomas G. (Tommy) Thompson, J.D.

Independent Director

--

Mr. Christopher A. Causey

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

-0.06%

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

20.57K

+6.14%

Prof. Nilda Mesa, J.D.

Independent Director

5.47K

+12.08%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

暂无数据

地区USD

名称

营收

占比

United States

749.60M

94.36%

Rest of World

44.80M

5.64%

业务

地区

暂无数据

股东统计

更新时间: 8月15日周五

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.79%

BlackRock Institutional Trust Company, N.A.

9.59%

Avoro Capital Advisors LLC

5.24%

State Street Global Advisors (US)

4.79%

Renaissance Technologies LLC

4.69%

其他

65.89%

持股股东

占比

The Vanguard Group, Inc.

9.79%

BlackRock Institutional Trust Company, N.A.

9.59%

Avoro Capital Advisors LLC

5.24%

State Street Global Advisors (US)

4.79%

Renaissance Technologies LLC

4.69%

其他

65.89%

股东类型

持股股东

占比

Investment Advisor

42.79%

Investment Advisor/Hedge Fund

37.76%

Hedge Fund

9.20%

Pension Fund

4.79%

Individual Investor

1.76%

Research Firm

1.73%

Bank and Trust

1.43%

Sovereign Wealth Fund

1.24%

Venture Capital

0.46%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

1338

46.42M

102.62%

-2.51M

2025Q1

1369

46.67M

103.49%

-1.81M

2024Q4

1344

46.07M

102.60%

-3.00M

2024Q3

1278

45.38M

101.97%

-7.63M

2024Q2

1219

48.02M

108.26%

-2.92M

2024Q1

1151

47.12M

106.59%

-2.41M

2023Q4

1127

46.52M

99.01%

-2.26M

2023Q3

1094

46.35M

98.80%

-3.96M

2023Q2

1068

46.82M

99.96%

-3.45M

2023Q1

1055

47.11M

101.08%

-1.09M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

4.44M

9.84%

+15.26K

+0.34%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.48M

9.93%

+12.87K

+0.29%

Mar 31, 2025

Avoro Capital Advisors LLC

2.67M

5.93%

-85.30K

-3.09%

Mar 31, 2025

State Street Global Advisors (US)

2.23M

4.95%

+30.71K

+1.40%

Mar 31, 2025

Renaissance Technologies LLC

2.11M

4.67%

+17.60K

+0.84%

Mar 31, 2025

Wellington Management Company, LLP

2.03M

4.49%

-437.48K

-17.76%

Mar 31, 2025

AQR Capital Management, LLC

908.45K

2.01%

-67.00K

-6.87%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.22M

2.71%

+85.70K

+7.53%

Mar 31, 2025

LSV Asset Management

902.32K

2%

-6.40K

-0.70%

Mar 31, 2025

Invesco Capital Management LLC

376.17K

0.83%

+246.08K

+189.17%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

Invesco Biotechnology & Genome ETF

4.45%

First Trust NASDAQ Pharmaceuticals ETF

3.62%

Formidable Fortress ETF

3.24%

First Trust NYSE Arca Biotechnology Index Fund

3.21%

Franklin Genomic Advancements ETF

3%

SPDR S&P Biotech ETF

2.53%

Inspire Faithward Mid Cap Momentum ETF

2.48%

Invesco Pharmaceuticals ETF

2.47%

Invesco S&P MidCap Quality ETF

2.41%

Alger Russell Innovation ETF

2.09%

Invesco Biotechnology & Genome ETF

占比4.45%

First Trust NASDAQ Pharmaceuticals ETF

占比3.62%

Formidable Fortress ETF

占比3.24%

First Trust NYSE Arca Biotechnology Index Fund

占比3.21%

Franklin Genomic Advancements ETF

占比3%

SPDR S&P Biotech ETF

占比2.53%

Inspire Faithward Mid Cap Momentum ETF

占比2.48%

Invesco Pharmaceuticals ETF

占比2.47%

Invesco S&P MidCap Quality ETF

占比2.41%

Alger Russell Innovation ETF

占比2.09%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

United Therapeutics Corp

307.617USD

United Therapeutics Corp

307.617

概览

公司

财务

分析